Please use this identifier to cite or link to this item: https://hdl.handle.net/11000/30860

Validation of a commercial allergen microarray platform for specific immunoglobulin E detection of respiratory and plant food allergens


no-thumbnailView/Open:

 Validation of a commercial allergen microarray platform for specific.pdf



576,51 kB
Adobe PDF
Share:

This resource is restricted

Title:
Validation of a commercial allergen microarray platform for specific immunoglobulin E detection of respiratory and plant food allergens
Authors:
Quan, Paola Leonor
Sabaté Brescó, Marina  
DAMELIO, CARMEN MARIANA  
Pascal, Mariona  
García, Blanca Esther
Gastaminza, Gabriel  
Blanca-López, Natalia
Alvarado, Maria Isabel
Fernández, Javier
Moya, Carmen
Bartra, Joan  
Ferrer, Marta  
Goikoetxea, María José  
Editor:
Elsevier
Department:
Departamentos de la UMH::Medicina Clínica
Issue Date:
2022-03
URI:
https://hdl.handle.net/11000/30860
Abstract:
Background: As the use of multiplex-specific immunoglobulin E (sIgE) detection methods becomes increasingly widespread, proper comparative validation assessments of emerging new platforms are vital. Objective: To evaluate the clinical and technical performance of a newly introduced microarray platform, Allergy Explorer (ALEX) (MacroArray Diagnostics), in the diagnosis of pollen (cypress, grass, olive), dust mite (Dermatophagoides pteronyssinus), mold (Alternaria alternata), fruit (apple, peach), and nut (walnut, hazelnut and peanut) allergies and to compare it with those of the ImmunoCAP Immuno Solid-phase Allergen Chip (ISAC) 112 microarray and the ImmunoCAP singleplex method (ThermoFisher Scientific). Methods: We enrolled 153 patients with allergy and 16 controls without atopy. The sIgE assays were conducted using ISAC112, ALEX version 2 (ALEX2), and ImmunoCAP for whole extracts and major components. Technical validation of ALEX2 was performed by measuring repeatability and interassay, interbatch, and interlaboratory reproducibility. Results: When measured globally (detection by 1 or more allergen components), ALEX2 had adequate sensitivity and specificity for most of the allergens studied, comparable in general with that of ISAC112 (except for olive pollen and walnut) and similar to that of ImmunoCAP whole extract measurements. Component-by-component analysis revealed comparable results for all techniques, except for Ole e 1 and Jug r 3, in both ISAC112 and ImmunoCAP comparisons, and Alt a 1, when compared with ISAC112. Continuous sIgE levels correlate with sIgE by ImmunoCAP. Good reproducibility and repeatability were observed for ALEX2.Conclusion: ALEX2 has sound technical performance and adequate diagnostic capacity, comparable in general with that of ISAC112 and ImmunoCAP.
Type of document:
application/pdf
Access rights:
info:eu-repo/semantics/closedAccess
DOI:
https://doi.org/10.1016/j.anai.2021.11.019
Appears in Collections:
Artículos Medicina Clínica



Creative Commons ???jsp.display-item.text9???